Drug Trial Radar · NCT01028924
Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers
Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 2009
Primary completion
Feb 2010
Study completion Apr 2010
Sponsor
- Lead sponsor
- NycomedIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (QT, QTc interval). Secondary objectives are the investigation of possible effects on heart rate and cardiac conduction (RR and PR intervals, QRS duration), pharmacokinetics and safety and tolerability in healthy subjects, and to determine the effect of the positive control, moxifloxacin, for sensitivity analysis. The trial will consist of a screening and a treatment phase of four treatment periods. There is a washout period of at least 7 days and 4 weeks at maximum between administrations. The expected total trial duration for the individual subject will be about 7 weeks (maximum 17) weeks.
Conditions
- Healthy
Interventions
TeduglutideDrug
subcutaneous (SC), single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- ECG measurement/assessment to determine the effect of a single dose of teduglutide on cardiac repolarisation (QT, QTc interval).Time frame: until 24 h post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nycomed GmbH
Konstanz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.